BDSX - Biodesix, Inc. Stock Analysis

Stock Taper

OPPORTUNITY RADAR SCREENER COMPARE ANY 2 STOCKS

BDSX

BIODESIX, INC.

NASDAQ

$29.06

▲ UP 4.83% (1.34)

KEY STATISTICS

Market Cap$238.10 M

52w High$31.97

52w Low$5.26

Dividend Yield—

Frequency—

P/E-9.17

Volume181.18K

Shares Out.8.14M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Scott Hutton

COMPENSATION 2026

Salary$643,404

Stock Awards$356,849

Incentive Plan Pay$710,280

All Other Comp.$3,500

Total$2,238,470

ABOUT

SECTOR

Healthcare

WENT PUBLIC

October 28, 2020

METHOD OF GOING PUBLIC

IPO

FULL TIME EMPLOYEES

334

PRICE TARGET

Target High$38.00

Target Low$32.00

Target Median$35.00

Target Consensus$35.00

UPCOMING EARNINGS

DateNov 2, 2026

DayMonday

Rev. Est.$27.55M

NOV

MON

SPLIT RECORD

DATE	TYPE	RATIO
2025-09-15	Reverse	1:20

ETFS HOLDING THIS STOCK

ETFS HOLDING

LISTED HERE

RANKED BY POSITION SIZE

INSTITUTIONAL OWNERSHIP

SHARES OWNED

40.17%

HOLDERS

TOP 8 OF 61 · RANKED BY POSITION SIZE

Aigh Capital Management LLC

758.3K sh

$11M

Telemark Asset Management, LLC

Soleus Capital Management, L.P.

Birchview Capital, LP

286.8K sh

$2.17M

Opaleye Management Inc.

PRICE

$29.06 ▲ UP 4.83% (+$1.34)

OVERLAYS

About Biodesix, Inc.

https://www.biodesix.com ↗

Biodesix, Inc. provides data-driven blood-based diagnostic tests for lung cancer risk assessment, mutation detection, and COVID-19, supporting clinical decision-making and biopharmaceutical research.

INDUSTRY

Medical - Diagnostics & Research

A PRODUCT BIODESIX, INC. IS KNOWN FOR

Nodify XL2

The Nodify XL2 is a blood-based proteomic test that helps clinicians identify likely benign lung nodules, supporting decision-making to reduce unnecessary invasive procedures for patients at low-to-moderate lung cancer risk.

COMPETITORS

COMPETITOR

Biodesix in 2025

SENTIMENT: + POSITIVE

EARNINGS · JANUARY 2026

Biodesix Announces Preliminary 2025 Financial Results Exceeding Guidance, Sparking Significant Stock Surge

Biodesix announced preliminary fourth-quarter and full-year 2025 financial results, reporting estimated full-year revenue of $88.5 million, which surpassed the high end of their increased guidance of $84-$86 million. This news, coupled with strong growth in their Lung Diagnostics testing revenue and the affirmation of achieving positive Adjusted EBITDA in the fourth quarter, led to a more than 40% surge in the company's stock price.

MARKET EXPANSION · THROUGHOUT 2025 · IN PROGRESS

Biodesix Strategically Expands into Primary Care Market to Drive Growth

In 2025, Biodesix made a significant strategic shift by expanding its commercial focus into the primary care physician (PCP) market. This move was aimed at driving earlier adoption of its lung diagnostic tests, such as the Nodify Lung nodule risk assessment, capturing patients at an earlier stage of their clinical journey.